Affordable Access

deepdyve-link
Publisher Website

Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America.

Authors
  • Wallace, Daniel J1
  • Tse, Karin2
  • Hanrahan, Leslie3
  • Davies, Rupert4
  • Petri, Michelle A5
  • 1 Rheumatology, Cedars-Sinai Medical Center, West Hollywood, California, USA.
  • 2 Lupus Foundation of America, Washington, District of Columbia, USA.
  • 3 Research and Education, Lupus Foundation of America, Washington, District of Columbia, USA.
  • 4 Blackrock Pharmaceuticals, Marlow, UK.
  • 5 Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Type
Published Article
Journal
Lupus Science & Medicine
Publisher
BMJ
Publication Date
Jan 01, 2019
Volume
6
Issue
1
Identifiers
DOI: 10.1136/lupus-2019-000317
PMID: 31168400
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a survey to assess the current landscape of HCQ tolerability and adherence.

Report this publication

Statistics

Seen <100 times